These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 30431083

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.
    Guan J, Xiao NJ, Chen M, Zhou WL, Zhang YW, Wang S, Dai YM, Li L, Zhang Y, Li QY, Li XZ, Yang M, Wu HB, Chen LH, Liu LY.
    Medicine (Baltimore); 2016 Jul; 95(30):e4421. PubMed ID: 27472739
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Value of 18F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients.
    Lv Z, Fan J, Xu J, Wu F, Huang Q, Guo M, Liao T, Liu S, Lan X, Liao S, Geng W, Jin Y.
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):735-750. PubMed ID: 29164298
    [Abstract] [Full Text] [Related]

  • 5. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
    Caicedo C, Garcia-Velloso MJ, Lozano MD, Labiano T, Vigil Diaz C, Lopez-Picazo JM, Gurpide A, Zulueta JJ, Richter Echevarria JA, Perez Gracia JL.
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
    [Abstract] [Full Text] [Related]

  • 6. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.
    Mak RH, Digumarthy SR, Muzikansky A, Engelman JA, Shepard JA, Choi NC, Sequist LV.
    Oncologist; 2011 Nov; 16(3):319-26. PubMed ID: 21339258
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Evaluate the value of (18)F-FDG PET-CT imaging in predicting the mutationsin epidermal growth factor receptor in lung adenocarcinoma].
    Ding CY, Yang WP, Guo Z, Sun J, Li YY, Li TR.
    Zhonghua Zhong Liu Za Zhi; 2017 Jul 23; 39(7):528-531. PubMed ID: 28728300
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs.
    Yoshida T, Tanaka H, Kuroda H, Shimizu J, Horio Y, Sakao Y, Inaba Y, Iwata H, Hida T, Yatabe Y.
    Lung Cancer; 2016 Oct 23; 100():14-19. PubMed ID: 27597275
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.
    Ko KH, Hsu HH, Huang TW, Gao HW, Shen DH, Chang WC, Hsu YC, Chang TH, Chu CM, Ho CL, Chang H.
    Eur J Nucl Med Mol Imaging; 2014 Oct 23; 41(10):1889-97. PubMed ID: 24852187
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer.
    Nakanishi K, Nakamura S, Sugiyama T, Kadomatsu Y, Ueno H, Goto M, Ozeki N, Fukui T, Iwano S, Chen-Yoshikawa TF.
    BMC Cancer; 2021 Sep 02; 21(1):983. PubMed ID: 34474680
    [Abstract] [Full Text] [Related]

  • 17. CD147-mediated glucose metabolic regulation contributes to the predictive role of 18 F-FDG PET/CT imaging for EGFR-TKI treatment sensitivity in NSCLC.
    Li X, Fu Q, Zhu Y, Wang J, Liu J, Yu X, Xu W.
    Mol Carcinog; 2019 Feb 02; 58(2):247-257. PubMed ID: 30320488
    [Abstract] [Full Text] [Related]

  • 18. Effect of Epidermal Growth Factor Receptor Mutation on Positron Emission Tomography/Computed Tomography in Lung Cancer.
    Park JS, Park HY, Choi Y.
    Anticancer Res; 2024 Jun 02; 44(6):2681-2687. PubMed ID: 38821597
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.